Enoxaparin in ACS

Enoxaparin versus UFH for STEMIOne Year Results fromExTRACT-TIMI 25E M. Antman, D. Morrow, C. McCabe, S. Murphy, H. White, K A A. Fox, and E.BraunwaldOn Behalf of the ExTRACT-TIMI 25 InvestigatorsProtocol DesignN = 20,506674 sites48 countriesSTEMI < 6 hLytic eligibleASALytic choice by MD(TNK, tPA, rPA, SK)Double-blind, blind, double-dummydummyENOX STRATEGY< 75 y: 30 mg IV bolusSC 1.0 mg / kg q 12 h (Hosp DC)≥ 75 y: No bolusSC 0.75mg / kg q 12 h (Hosp DC) )CrCl < 30: 1.0 mg / kg q 24 hUFH STRATEGY60 U / kg bolus (4000U)Inf 12 U/kg/h(1000/ U/h)Duration: at least 48 hCont’d at MD discretion1° Efficacy Endpoint: Death or Nonfatal MI at 30 daysAdditional F/U at 6 mo and 1 yr